JAZZ vs. PRGO, CORT, ELAN, CYTK, APLS, VKTX, CERE, IONS, ITCI, and ASND
Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Perrigo (PRGO), Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS), Viking Therapeutics (VKTX), Cerevel Therapeutics (CERE), Ionis Pharmaceuticals (IONS), Intra-Cellular Therapies (ITCI), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical preparations" industry.
Perrigo (NYSE:PRGO) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.
Perrigo presently has a consensus target price of $40.67, indicating a potential upside of 27.32%. Jazz Pharmaceuticals has a consensus target price of $195.08, indicating a potential upside of 78.22%. Given Perrigo's higher possible upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Perrigo.
95.9% of Perrigo shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 0.7% of Perrigo shares are held by company insiders. Comparatively, 4.4% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Jazz Pharmaceuticals has a net margin of 10.82% compared to Jazz Pharmaceuticals' net margin of -0.27%. Perrigo's return on equity of 31.27% beat Jazz Pharmaceuticals' return on equity.
In the previous week, Perrigo had 2 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 11 mentions for Perrigo and 9 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.80 beat Perrigo's score of 0.70 indicating that Perrigo is being referred to more favorably in the media.
Jazz Pharmaceuticals has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals received 331 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 80.49% of users gave Jazz Pharmaceuticals an outperform vote while only 66.78% of users gave Perrigo an outperform vote.
Perrigo has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.
Summary
Jazz Pharmaceuticals beats Perrigo on 12 of the 18 factors compared between the two stocks.
Get Jazz Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jazz Pharmaceuticals Competitors List
Related Companies and Tools
